Scarica l'app Stockscreener
9.48
2.27%
-0.22
Pre-mercato:
9.20
-0.28
-2.95%
Precedente Chiudi:
$9.70
Aprire:
$9.74
Volume 24 ore:
209.46K
Relative Volume:
0.48
Capitalizzazione di mercato:
$166.40M
Reddito:
$1.54M
Utile/perdita netta:
$-38.70M
Rapporto P/E:
-2.03
EPS:
-4.67
Flusso di cassa netto:
$-36.86M
1 W Prestazione:
-8.58%
1M Prestazione:
-14.36%
6M Prestazione:
+7.36%
1 anno Prestazione:
-37.14%
Intervallo 1D:
$9.44
$9.90
Intervallo di 1 settimana:
$9.44
$11.64
Portata 52W:
$4.64
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Nome
Corbus Pharmaceuticals Holdings Inc
Settore
Industria
Telefono
617-963-0103
Indirizzo
500 RIVER RIDGE DRIVE, NORWOOD, MA
Confronta CRBP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
9.48 | 170.26M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | B. Riley Securities | Buy |
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Iniziato | Wedbush | Outperform |
| 2024-07-22 | Ripresa | H.C. Wainwright | Buy |
| 2024-06-26 | Iniziato | B. Riley Securities | Buy |
| 2024-06-03 | Reiterato | Oppenheimer | Outperform |
| 2024-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-03-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-09-08 | Downgrade | BTIG Research | Buy → Neutral |
| 2020-09-08 | Downgrade | Jefferies | Buy → Hold |
| 2020-09-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2020-07-07 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-03-26 | Iniziato | Nomura | Buy |
| 2019-04-05 | Iniziato | Jefferies | Buy |
| 2019-03-20 | Iniziato | Oppenheimer | Outperform |
| 2019-01-11 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-10-24 | Iniziato | B. Riley FBR | Buy |
| 2018-01-19 | Iniziato | Raymond James | Outperform |
| 2017-12-14 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-11-08 | Reiterato | Noble Financial | Buy |
| 2017-09-29 | Ripresa | Noble Financial | Buy |
| 2017-03-30 | Reiterato | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-11 | Reiterato | Noble Financial | Buy |
Mostra tutto
Corbus Pharmaceuticals Holdings Inc Borsa (CRBP) Ultime notizie
Cormorant Asset Management, Lp Sells 30,029 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock - MarketBeat
Discipline and Rules-Based Execution in CRBP Response - news.stocktradersdaily.com
CRBP stock surged 36% pre-market – what did its obesity treatment drug study reveal? - MSN
Corbus Pharmaceuticals (CRBP) Reports Phase 1 Study Results for Obesity Drug - GuruFocus
Corbus declines following early-stage results on oral obesity asset CRB-913 (CRBP:NASDAQ) - Seeking Alpha
CRBP Stock Surged 36% Pre-Market – What Did Its Obesity Treatment Drug Study Reveal? - Stocktwits
CRBP: Corbus Pharmaceuticals' Promising Phase I Study Sparks Int - GuruFocus
CRBP: CRB-913 induced rapid, significant weight loss with minimal side effects in early obesity trials - TradingView — Track All Markets
Corbus Pharmaceuticals Reports Phase 1a Obesity Drug Data Showing Weight Loss - marketscreener.com
Corbus reports positive phase 1 results for obesity drug CRB-913 - Investing.com
Corbus Pharmaceuticals Advances Obesity Treatment with CRB-913 - TipRanks
Corbus Pharmaceuticals Reports Results From Phase 1A Study Of Oral CB1 Inverse Agonist CRB-913 For The Treatment For Obesity Demonstrating Favorable Safety Profile And Emerging Evidence Of Weight Loss - TradingView — Track All Markets
Corbus Pharmaceuticals (CRBP) Advances Obesity Treatment with CR - GuruFocus
Corbus Pharmaceuticals Announces Phase 1a Study Results of CRB-913 - TradingView — Track All Markets
Corbus Pharmaceuticals stock rises after promising obesity drug safety data By Investing.com - Investing.com UK
Corbus Pharmaceuticals stock rises after promising obesity drug safety data - Investing.com
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss - GlobeNewswire
Corbus to release phase 1a study results for obesity drug CRB-913 - Investing.com
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 - The Manila Times
Corbus Pharmaceuticals to Announce Phase 1a Results for CRB-913 on December 11, 2025 - Quiver Quantitative
Corbus Pharmaceuticals (NASDAQ: CRBP) to release Phase 1a CRB-913 obesity data on Dec. 11 - Stock Titan
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains - 富途牛牛
Will Corbus Pharmaceuticals Holdings Inc. stock remain a Wall Street favoriteMarket Sentiment Summary & Free Weekly Chart Analysis and Trade Guides - Newser
Why Corbus Pharmaceuticals Holdings Inc. (3371) stock trades below fair valueInsider Selling & Free Expert Verified Stock Movement Alerts - Newser
Why Corbus Pharmaceuticals Holdings Inc. (3371) stock attracts wealthy investorsEntry Point & Advanced Technical Signal Analysis - Newser
What risks investors should watch in Corbus Pharmaceuticals Holdings Inc. stock2025 AllTime Highs & Intraday High Probability Alerts - Newser
Is Corbus Pharmaceuticals Holdings Inc. (3371) stock a top dividend aristocrat candidate2025 Big Picture & Real-Time Volume Surge Alerts - Newser
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Is Corbus Pharmaceuticals Holdings Inc. (3371) stock bottoming after sell offStop Loss & Free Weekly Watchlist of Top Performers - Newser
Corbus Pharmaceuticals (CRBP) Stock Analysis Report | Financials & Insights - Benzinga
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Behavioral Patterns of CRBP and Institutional Flows - news.stocktradersdaily.com
Why Corbus Pharmaceuticals Holdings Inc. (3371) stock could be top winnerForecast Cut & AI Driven Stock Movement Reports - Newser
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
B. Riley Forecasts Lower Earnings for Corbus Pharmaceuticals - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
What analysts say about Corbus Pharmaceuticals Holdings Inc 3371 stockSector Performance Drivers & Free Trading Psychology Sessions - earlytimes.in
What is B. Riley’s Forecast for CRBP FY2029 Earnings? - Defense World
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
(CRBP) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
How interest rate cuts could boost Corbus Pharmaceuticals Holdings Inc. stockPortfolio Performance Summary & Free Long-Term Investment Growth Plans - newser.com
Cannabis Pharmaceuticals Market | Global Market Analysis Report2035 - Fact.MR
Can Corbus Pharmaceuticals Holdings Inc. (3371) stock sustain margin levelsWeekly Gains Summary & High Return Trade Opportunity Guides - newser.com
Is Corbus Pharmaceuticals Holdings Inc. (3371) stock a top hedge fund pickEarnings Beat & AI Enhanced Trading Signals - newser.com
Can Corbus Pharmaceuticals Holdings Inc. stock surprise with earnings upside2025 Investor Takeaways & Safe Entry Momentum Tips - newser.com
What analyst consensus says on Corbus Pharmaceuticals Holdings Inc. stock2025 Technical Overview & Fast Momentum Stock Entry Tips - newser.com
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc Azioni (CRBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):